Georgiana K. Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Georgiana K. Ellis has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Julie R. Gralow
From the Seattle Cancer Care Alliance; Southwest Oncology Group Statistical Center, Seattle, WA; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Southern California, Norris Cancer Hospital, Los Angeles, CA; University of New Mexico, Cancer Research and Treatment Center, Albuquerque, NM; Mayo Clinic, Jacksonville, FL; and Arizona Cancer Center, Tucson, AZ
3 shared publications- R. B. Livingston
University of Arizona, Tucson, AZ
3 shared publications - David A. Mankoff
Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
2 shared publications Devchand Paul
US Oncology
2 shared publicationsH. M. Linden
Seattle Cancer Care Alliance, Seattle, WA; Univ of Washington, Seattle, WA
2 shared publicationsHenry G. Bone
Michigan Bone & Mineral Clinic
2 shared publications
Latest Publications
- 10 March 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (8) , 1014-1021
Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012
Purpose: Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 weeks (continuous arm). All patients had subsequent weekly paclitaxel for 12 weeks before surgery. Patients and Methods: Patients (n = 372) were randomly assigned to the standard arm (n = 186) or the continuous arm (n = 186) stratified by disease type (LABC, n = 256; IBC, n = 116). The primary outcome was microscopic pathologic complete response (pCR) at surgery. Secondary outcomes included disease-free survival, overall survival, and toxicity. Results: More patients in the standard arm had grade 3 to 4 leukopenia and neutropenia, but there were more instances of stomatitis/pharyngitis and hand-foot skin reaction in the continuous arm. Assessed among 356 eligible patients, pCR was not different between the treatment groups stratified by disease type (P = .42). In subset analysis, higher pCR rates were observed in the continuous arm versus the standard arm only for stage IIIB disease (P = .0057) and in IBC (P = .06). Comparison of overall survival and disease-free survival showed no difference between treatment groups (P = .37 and P = .87, respectively). Conclusion: No significant clinical benefit was seen for the investigational arm in this trial overall.
- 10 March 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (8) , 1014-1021
Phase III Comparison of Standard Doxorubicin and Cyclophosphamide Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer: SWOG 0012
Purpose: Patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) were randomly assigned to 21-day doxorubicin and cyclophosphamide administered for five cycles (standard arm) versus weekly doxorubicin and daily oral cyclophosphamide administered with granulocyte colony-stimulating factor support for 15 weeks (continuous arm). All patients had subsequent weekly paclitaxel for 12 weeks before surgery. Patients and Methods: Patients (n = 372) were randomly assigned to the standard arm (n = 186) or the continuous arm (n = 186) stratified by disease type (LABC, n = 256; IBC, n = 116). The primary outcome was microscopic pathologic complete response (pCR) at surgery. Secondary outcomes included disease-free survival, overall survival, and toxicity. Results: More patients in the standard arm had grade 3 to 4 leukopenia and neutropenia, but there were more instances of stomatitis/pharyngitis and hand-foot skin reaction in the continuous arm. Assessed among 356 eligible patients, pCR was not different between the treatment groups stratified by disease type (P = .42). In subset analysis, higher pCR rates were observed in the continuous arm versus the standard arm only for stage IIIB disease (P = .0057) and in IBC (P = .06). Comparison of overall survival and disease-free survival showed no difference between treatment groups (P = .37 and P = .87, respectively). Conclusion: No significant clinical benefit was seen for the investigational arm in this trial overall.
- 24 March 2009
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 118 (1) , 81-87
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Denosumab increased lumbar spine bone mineral density (BMD) versus placebo in a 2-year, randomized, placebo-controlled, phase 3 study of patients with hormone-receptor-positive, non-metastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy. In subgroup analyses at 12 and 24 months, we evaluated factors (duration and type of aromatase inhibitor, tamoxifen use, age, time since menopause, body mass index, T-score) that might influence BMD at the lumbar spine, total hip, femoral neck, and 1/3 radius. Patients were randomized to receive placebo (n = 125) or 60 mg denosumab (n = 127) subcutaneously every 6 months. In all subgroups, 12 or 24 months’ treatment with denosumab was associated with larger BMD gains than placebo across multiple skeletal sites. Most increases were statistically significant (P < 0.05). Twice-yearly administration of denosumab, regardless of patient subgroup or skeletal site, resulted in consistent increases in BMD versus placebo at 12 and 24 months.
- 24 March 2009
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 118 (1) , 81-87
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Denosumab increased lumbar spine bone mineral density (BMD) versus placebo in a 2-year, randomized, placebo-controlled, phase 3 study of patients with hormone-receptor-positive, non-metastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy. In subgroup analyses at 12 and 24 months, we evaluated factors (duration and type of aromatase inhibitor, tamoxifen use, age, time since menopause, body mass index, T-score) that might influence BMD at the lumbar spine, total hip, femoral neck, and 1/3 radius. Patients were randomized to receive placebo (n = 125) or 60 mg denosumab (n = 127) subcutaneously every 6 months. In all subgroups, 12 or 24 months’ treatment with denosumab was associated with larger BMD gains than placebo across multiple skeletal sites. Most increases were statistically significant (P < 0.05). Twice-yearly administration of denosumab, regardless of patient subgroup or skeletal site, resulted in consistent increases in BMD versus placebo at 12 and 24 months.
- Top Cited Papers
- 20 October 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (30) , 4875-4882
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Purpose: Adjuvant aromatase inhibitor therapy is well established in postmenopausal women with hormone receptor–positive breast cancer, but such therapy is complicated by accelerated bone loss and increased fracture risk. We investigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand, to protect against aromatase inhibitor–induced bone loss.Patients and Methods: Eligible women with hormone receptor–positive nonmetastatic breast cancer treated with adjuvant aromatase inhibitor therapy were stratified by duration of aromatase inhibitor therapy (≤ 6 v > 6 months), received supplemental calcium and vitamin D, and were randomly assigned to receive placebo (n = 125) or subcutaneous denosumab 60 mg (n = 127) every 6 months. At enrollment, all patients were required to have evidence of low bone mass, excluding osteoporosis. The primary end point was percentage change from baseline at month 12 in lumbar spine bone mineral density (BMD).Results: At 12 and 24 months, lumbar spine BMD increased by 5.5% and 7.6%, respectively, in the denosumab group versus placebo (P < .0001 at both time points). Increases were observed as early as 1 month and were not influenced by duration of aromatase inhibitor therapy. Increases in BMD were also observed at the total hip, total body, femoral neck, and the predominantly cortical one-third radius. Bone turnover markers decreased with denosumab treatment. Overall incidence of treatment-emergent adverse events (AEs) was similar between treatment groups.Conclusion: In women with nonmetastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy, twice-yearly administration of denosumab led to significant increases in BMD over 24 months at trabecular and cortical bone, with overall AE rates similar to those of placebo.
- 20 October 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (30) , 4875-4882
Top Cited PapersRandomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Purpose: Adjuvant aromatase inhibitor therapy is well established in postmenopausal women with hormone receptor–positive breast cancer, but such therapy is complicated by accelerated bone loss and increased fracture risk. We investigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand, to protect against aromatase inhibitor–induced bone loss.Patients and Methods: Eligible women with hormone receptor–positive nonmetastatic breast cancer treated with adjuvant aromatase inhibitor therapy were stratified by duration of aromatase inhibitor therapy (≤ 6 v > 6 months), received supplemental calcium and vitamin D, and were randomly assigned to receive placebo (n = 125) or subcutaneous denosumab 60 mg (n = 127) every 6 months. At enrollment, all patients were required to have evidence of low bone mass, excluding osteoporosis. The primary end point was percentage change from baseline at month 12 in lumbar spine bone mineral density (BMD).Results: At 12 and 24 months, lumbar spine BMD increased by 5.5% and 7.6%, respectively, in the denosumab group versus placebo (P < .0001 at both time points). Increases were observed as early as 1 month and were not influenced by duration of aromatase inhibitor therapy. Increases in BMD were also observed at the total hip, total body, femoral neck, and the predominantly cortical one-third radius. Bone turnover markers decreased with denosumab treatment. Overall incidence of treatment-emergent adverse events (AEs) was similar between treatment groups.Conclusion: In women with nonmetastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy, twice-yearly administration of denosumab led to significant increases in BMD over 24 months at trabecular and cortical bone, with overall AE rates similar to those of placebo.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 546
Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy
546 Background: In postmenopausal women with breast cancer, adjuvant AI therapy contributes to accelerated bone loss and risk for fracture. Denosumab, a fully human monoclonal antibody to RANKL, inhibits osteoclast-mediated bone loss. Methods: In this 2-year, double-blind, placebo-controlled study, we evaluated factors that may influence BMD in patients (pts) ≥ 18 years old with hormone receptor-positive breast cancer who were receiving adjuvant AI therapy and had evidence of low bone mass. Pts were stratified by duration of prior AI therapy (≤ 6 vs >6 months) and randomized to receive, together with calcium and vitamin D, placebo (n = 125) or 60 mg denosumab (n = 127) subcutaneously every 6 months for 4 doses. A sample size of 104 pts/group was planned to provide 95% power to detect a 2% difference between groups (α = 0.05). An analysis of covariance model was used for subgroup analyses, adjusting for treatment, stratification factor, baseline BMD value, densitometer type, and baseline BMD value-by-densitometer-type interaction. The primary endpoint was the percentage change from baseline to month 12 in lumbar spine BMD (Ellis G et al, 2007 SABCS Annual Meeting). We present a subgroup analysis (post-hoc) of the percentage change in BMD at the lumbar spine, total hip, femoral neck, and distal 1/3 radius at 12 months. Results: At all anatomic sites, representing both trabecular and cortical bone, denosumab consistently increased BMD compared with placebo at month 12; this increase was consistent regardless of site or subgroup (Table). The incidences of adverse events (AEs) (91% denosumab, 90% placebo) were similar in both groups. Conclusions: Twice-yearly administration of denosumab resulted in consistent increases from baseline compared with placebo in BMD at month 12 across the skeleton, regardless of subgroups, with an overall adverse event profile that was similar to that seen for placebo.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 546
Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy
546 Background: In postmenopausal women with breast cancer, adjuvant AI therapy contributes to accelerated bone loss and risk for fracture. Denosumab, a fully human monoclonal antibody to RANKL, inhibits osteoclast-mediated bone loss. Methods: In this 2-year, double-blind, placebo-controlled study, we evaluated factors that may influence BMD in patients (pts) ≥ 18 years old with hormone receptor-positive breast cancer who were receiving adjuvant AI therapy and had evidence of low bone mass. Pts were stratified by duration of prior AI therapy (≤ 6 vs >6 months) and randomized to receive, together with calcium and vitamin D, placebo (n = 125) or 60 mg denosumab (n = 127) subcutaneously every 6 months for 4 doses. A sample size of 104 pts/group was planned to provide 95% power to detect a 2% difference between groups (α = 0.05). An analysis of covariance model was used for subgroup analyses, adjusting for treatment, stratification factor, baseline BMD value, densitometer type, and baseline BMD value-by-densitometer-type interaction. The primary endpoint was the percentage change from baseline to month 12 in lumbar spine BMD (Ellis G et al, 2007 SABCS Annual Meeting). We present a subgroup analysis (post-hoc) of the percentage change in BMD at the lumbar spine, total hip, femoral neck, and distal 1/3 radius at 12 months. Results: At all anatomic sites, representing both trabecular and cortical bone, denosumab consistently increased BMD compared with placebo at month 12; this increase was consistent regardless of site or subgroup (Table). The incidences of adverse events (AEs) (91% denosumab, 90% placebo) were similar in both groups. Conclusions: Twice-yearly administration of denosumab resulted in consistent increases from baseline compared with placebo in BMD at month 12 across the skeleton, regardless of subgroups, with an overall adverse event profile that was similar to that seen for placebo.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 633
Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
633 Background: The response of bone-dominant breast cancer to therapy is difficult to assess by conventional imaging approaches such as bone scan and MRI. Our preliminary studies have previously shown that quantitative serial [F-18]-2-fluoro-D-glucose positron emission tomography (FDG PET) correlates with therapeutic response of bone-dominant breast cancer, but the relationship to long-term outcome measures is unknown. The aim of this study is to evaluate the prognostic power of FDG PET imaging in bone-dominant breast cancer undergoing treatment. Methods: A retrospective analysis was performed on the medical records of 405 breast cancer patients who were previously referred for FDG PET between January 1999 and December 2003. From this population of patients, 29 patients were selected who demonstrated metastatic bone only +/- nodal breast cancer and were undergoing treatment with at least 2 serial PET scans which had clear uptake. The standard uptake value (SUV) changes for the most conspicuous bone lesion were compared to long-term prognostic outcomes (TTP, time to skeletal-related event(t-SRE), and time to death(TTD)). Time-to-progression was defined as the time from the initial index FDG PET to disease progression (>25% increase in tumor markers, clear symptomatic progression, progression on some other imaging modality, skeletal-related events, or a new lesion). A skeletal-related event was defined by hypercalcemia, radiation therapy to stabilize disease, pathologic fracture, cord compression, or surgery to stabilize spine. Results: Using hazard analysis, longer TTP correlated with greater decreases in SUV either by absolute or percentage changes. T-SRE was found to significantly correlate with higher initial SUV readings. In addition, when grouped by tertiles for absolute SUV changes, the smallest and largest tertile groups correlated with t-SRE. No correlation was demonstrated for TTD and SUV changes, however only one death occurred during this study analysis. Conclusions: Preliminary results indicate that serial FDG PET predicts TTP and t-SRE in bone-dominant breast cancer; however, larger prospective trials are needed. Supported by CA72064, CA42045, and BCRF No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 633
Serial FDG-PET to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
633 Background: The response of bone-dominant breast cancer to therapy is difficult to assess by conventional imaging approaches such as bone scan and MRI. Our preliminary studies have previously shown that quantitative serial [F-18]-2-fluoro-D-glucose positron emission tomography (FDG PET) correlates with therapeutic response of bone-dominant breast cancer, but the relationship to long-term outcome measures is unknown. The aim of this study is to evaluate the prognostic power of FDG PET imaging in bone-dominant breast cancer undergoing treatment. Methods: A retrospective analysis was performed on the medical records of 405 breast cancer patients who were previously referred for FDG PET between January 1999 and December 2003. From this population of patients, 29 patients were selected who demonstrated metastatic bone only +/- nodal breast cancer and were undergoing treatment with at least 2 serial PET scans which had clear uptake. The standard uptake value (SUV) changes for the most conspicuous bone lesion were compared to long-term prognostic outcomes (TTP, time to skeletal-related event(t-SRE), and time to death(TTD)). Time-to-progression was defined as the time from the initial index FDG PET to disease progression (>25% increase in tumor markers, clear symptomatic progression, progression on some other imaging modality, skeletal-related events, or a new lesion). A skeletal-related event was defined by hypercalcemia, radiation therapy to stabilize disease, pathologic fracture, cord compression, or surgery to stabilize spine. Results: Using hazard analysis, longer TTP correlated with greater decreases in SUV either by absolute or percentage changes. T-SRE was found to significantly correlate with higher initial SUV readings. In addition, when grouped by tertiles for absolute SUV changes, the smallest and largest tertile groups correlated with t-SRE. No correlation was demonstrated for TTD and SUV changes, however only one death occurred during this study analysis. Conclusions: Preliminary results indicate that serial FDG PET predicts TTP and t-SRE in bone-dominant breast cancer; however, larger prospective trials are needed. Supported by CA72064, CA42045, and BCRF No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 628
Adjuvant weekly “AC+G” followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up
628 We have previously reported DFS for the adjuvant treatment of node-positive breast cancer with a median of 4 involved nodes of 86% at 5 years using a 20–24 week regimen of weekly doxorubicin (20–24 mg/m2), daily oral cyclophosphamide (60 mg/m2) ± weekly 5FU (300 mg/m2) and scheduled filgrastim support (5 mcg/kg/day, days 2–7) (“ AC+G,” Ellis G et al JCO 2002 20(17): 3637–3643). We report now on 54 patients treated on a Seattle Cancer Care Alliance/University of Washington successor study with 12 weeks of AC+G followed by 12 weeks of weekly paclitaxel (80 mg/m2). Median age was 50. Median number of involved nodes was 5, with 33% having 1–3, 39% with 4–9, and 28% > 10 involved nodes 41/54 patients had either 4 or more involved nodes, OR ER/PR negative disease OR HER-2/neu positive disease (3+ by IHC, or FISH+). Eighty percent had ER positive disease, 22% had HER-2/neu positive disease. Grade 3–4 toxicities, for the “ AC+G” or paclitaxel portion of treatment, were as follows, respectively: neutropenia 11%, 23% febrile neutropenia 0%, 2% mucositis 6%, 0% hand-foot syndrome 7%, 0% RBC transfusion 4%, 2% nausea, vomiting 2%, 0%. Additional hormonal therapy was administered for patients with ER or PR positive disease: tamoxifen in 31%, tamoxifen followed by an aromatase inhibitor, 13% aromatase inhibitor 31% aromatase inhibitor followed by tamoxifen 2%. Disease-free survival at 3 years is 90% compared to 86% in the previous study, (F)AC+G. By way of further comparison, Citron et al reported a DFS of 82% at 4 years for CALGB 9741 for patients with a median of 3 positive nodes.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 628
Adjuvant weekly “AC+G” followed by weekly paclitaxel shows good efficacy in node-positive breast cancer at two years median follow-up
628 We have previously reported DFS for the adjuvant treatment of node-positive breast cancer with a median of 4 involved nodes of 86% at 5 years using a 20–24 week regimen of weekly doxorubicin (20–24 mg/m2), daily oral cyclophosphamide (60 mg/m2) ± weekly 5FU (300 mg/m2) and scheduled filgrastim support (5 mcg/kg/day, days 2–7) (“ AC+G,” Ellis G et al JCO 2002 20(17): 3637–3643). We report now on 54 patients treated on a Seattle Cancer Care Alliance/University of Washington successor study with 12 weeks of AC+G followed by 12 weeks of weekly paclitaxel (80 mg/m2). Median age was 50. Median number of involved nodes was 5, with 33% having 1–3, 39% with 4–9, and 28% > 10 involved nodes 41/54 patients had either 4 or more involved nodes, OR ER/PR negative disease OR HER-2/neu positive disease (3+ by IHC, or FISH+). Eighty percent had ER positive disease, 22% had HER-2/neu positive disease. Grade 3–4 toxicities, for the “ AC+G” or paclitaxel portion of treatment, were as follows, respectively: neutropenia 11%, 23% febrile neutropenia 0%, 2% mucositis 6%, 0% hand-foot syndrome 7%, 0% RBC transfusion 4%, 2% nausea, vomiting 2%, 0%. Additional hormonal therapy was administered for patients with ER or PR positive disease: tamoxifen in 31%, tamoxifen followed by an aromatase inhibitor, 13% aromatase inhibitor 31% aromatase inhibitor followed by tamoxifen 2%. Disease-free survival at 3 years is 90% compared to 86% in the previous study, (F)AC+G. By way of further comparison, Citron et al reported a DFS of 82% at 4 years for CALGB 9741 for patients with a median of 3 positive nodes.
- 1 September 2002
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (17) , 3637-3643
Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer
PURPOSE: Theoretical considerations and clinical experience suggest that dose-dense chemotherapy may be superior to other approaches using the same drugs. We studied a dose-dense combination of doxorubicin and cyclophosphamide, with or without fluorouracil, as adjuvant therapy. PATIENTS AND METHODS: Patients with resected breast cancer were treated if they were node-positive and estrogen receptor–negative, positive for overexpression of Her-2-neu, or had four or more involved nodes. Doxorubicin was given weekly to a total dose of 480 mg/m2. Cyclophosphamide 60 mg/m2 was given daily by mouth during the period of doxorubicin treatment. The first 30 patients received fluorouracil at 300 mg/m2/wk intravenously concurrently with doxorubicin administration. In the last 22, it was omitted because of symptomatic hand-foot syndrome in the majority of patients. Filgrastim (granulocyte colony-stimulating factor [G-CSF]) was administered during chemotherapy every day except the day of intravenous administration and continued until 1 week after the completion of the chemotherapy. RESULTS: Between October 20, 1992, and June 10, 1997, we enrolled 52 patients. The mean delivered dose-intensity for doxorubicin was 18.6 mg/m2/wk. Hospitalization was required in 6% of patients for reversible febrile neutropenia. There were no acute treatment-related deaths, but one patient subsequently died of acute leukemia with a characteristic translocation for anthracycline-related exposure. At 5 years, the event-free survival was 86% for all patients (95% confidence interval, 75% to 95%). CONCLUSION: Continuous dose-dense chemotherapy with G-CSF support produced encouraging results, which seem to be superior to those expected with “standard” doxorubicin and cyclophosphamide chemotherapy. It deserves a test in the form of a randomized trial where this approach to anthracycline-based treatment is compared with intermittent administration.
- 1 September 2002
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (17) , 3637-3643
Dose-Dense Anthracycline-Based Chemotherapy for Node-Positive Breast Cancer
PURPOSE: Theoretical considerations and clinical experience suggest that dose-dense chemotherapy may be superior to other approaches using the same drugs. We studied a dose-dense combination of doxorubicin and cyclophosphamide, with or without fluorouracil, as adjuvant therapy. PATIENTS AND METHODS: Patients with resected breast cancer were treated if they were node-positive and estrogen receptor–negative, positive for overexpression of Her-2-neu, or had four or more involved nodes. Doxorubicin was given weekly to a total dose of 480 mg/m2. Cyclophosphamide 60 mg/m2 was given daily by mouth during the period of doxorubicin treatment. The first 30 patients received fluorouracil at 300 mg/m2/wk intravenously concurrently with doxorubicin administration. In the last 22, it was omitted because of symptomatic hand-foot syndrome in the majority of patients. Filgrastim (granulocyte colony-stimulating factor [G-CSF]) was administered during chemotherapy every day except the day of intravenous administration and continued until 1 week after the completion of the chemotherapy. RESULTS: Between October 20, 1992, and June 10, 1997, we enrolled 52 patients. The mean delivered dose-intensity for doxorubicin was 18.6 mg/m2/wk. Hospitalization was required in 6% of patients for reversible febrile neutropenia. There were no acute treatment-related deaths, but one patient subsequently died of acute leukemia with a characteristic translocation for anthracycline-related exposure. At 5 years, the event-free survival was 86% for all patients (95% confidence interval, 75% to 95%). CONCLUSION: Continuous dose-dense chemotherapy with G-CSF support produced encouraging results, which seem to be superior to those expected with “standard” doxorubicin and cyclophosphamide chemotherapy. It deserves a test in the form of a randomized trial where this approach to anthracycline-based treatment is compared with intermittent administration.
- 1 June 1999
- Vol. 85 (11) , 2410-23
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mammographic and physical examination assessments of the response of locally advanced breast carcinoma (LABC) to neoadjuvant therapy have been shown to be inaccurate. The authors studied the feasibility and accuracy of [technetium 99m]-sestamibi (MIBI) for monitoring the response of patients with LABC to neoadjuvant chemotherapy. Patients receiving neoadjuvant chemotherapy for LABC underwent prone lateral scintimammography before therapy, after 2 months of therapy, and close to the completion of chemotherapy (presurgery) if chemotherapy continued for >3 months. Images were analyzed both qualitatively and quantitatively using the lesion-to-normal breast MIBI uptake ratio (L:N). Imaging results were compared with the clinical response and the pathologic response as determined from the posttherapy surgical specimen. A total of 32 patients (29 who were assessable for primary tumor response and 28 who were assessable for lymph node response) were included in the study. The mean change in the primary tumor L:N MIBI uptake ratio after 2 months of chemotherapy was -35% for clinical responders and +17% for nonresponders (P or =40% in the MIBI uptake ratio identified CRs with 100% sensitivity and 89% specificity. Pretherapy imaging predicted axillary lymph node metastases in 85% of patients ultimately found to have > or =1 positive lymph nodes at surgery, but was less accurate in identifying residual lymph node disease after therapy (55% sensitivity and 75% specificity). MIBI imaging accurately assessed the response to neoadjuvant chemotherapy in patients with LABC. Further studies are needed to determine the role of MIBI in this group of patients.
- 1 June 1999
- Vol. 85 (11) , 2410-23
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography.
Mammographic and physical examination assessments of the response of locally advanced breast carcinoma (LABC) to neoadjuvant therapy have been shown to be inaccurate. The authors studied the feasibility and accuracy of [technetium 99m]-sestamibi (MIBI) for monitoring the response of patients with LABC to neoadjuvant chemotherapy. Patients receiving neoadjuvant chemotherapy for LABC underwent prone lateral scintimammography before therapy, after 2 months of therapy, and close to the completion of chemotherapy (presurgery) if chemotherapy continued for >3 months. Images were analyzed both qualitatively and quantitatively using the lesion-to-normal breast MIBI uptake ratio (L:N). Imaging results were compared with the clinical response and the pathologic response as determined from the posttherapy surgical specimen. A total of 32 patients (29 who were assessable for primary tumor response and 28 who were assessable for lymph node response) were included in the study. The mean change in the primary tumor L:N MIBI uptake ratio after 2 months of chemotherapy was -35% for clinical responders and +17% for nonresponders (P or =40% in the MIBI uptake ratio identified CRs with 100% sensitivity and 89% specificity. Pretherapy imaging predicted axillary lymph node metastases in 85% of patients ultimately found to have > or =1 positive lymph nodes at surgery, but was less accurate in identifying residual lymph node disease after therapy (55% sensitivity and 75% specificity). MIBI imaging accurately assessed the response to neoadjuvant chemotherapy in patients with LABC. Further studies are needed to determine the role of MIBI in this group of patients.
- 1 May 1999
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (5) , 1407
Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy With Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I-II Study of Doxorubicin-Treated Patients
PURPOSE: We investigated 96-hour paclitaxel infusion combined with weekly (days eight and 15) vinorelbine as salvage therapy for metastatic breast cancer in anthracycline-exposed patients. All patients received scheduled support with granulocyte colony-stimulating factor (G-CSF; filgrastim). Tumor response, toxicity, time to progression (TTP), and survival were assessed. PATIENTS AND METHODS: This single-center nonrandomized trial enrolled 32 patients. Anthracycline exposure and subsequent progression were common to all patients. Paclitaxel and vinorelbine were escalated over three dosing levels, stratified by liver function. RESULTS: Seven patients (22%) achieved a complete response and nine patients achieved a partial response for an overall response rate of 50%. The median TTP was 6.1 months, and median survival time was 14.1 months. Dose-limiting toxicity was neutropenia, with dose delay or reduction in seven of 32 patients. Febrile neutropenia requiring hospitalization was uncommon (three of 32 patients; 9%). There were no treatment-related deaths. Grade 3/4 thrombocytopenia occurred in two patients (6%), and 13 patients (41%) required RBC transfusions for anemia. Grade 3 nausea and vomiting was seen in one patient, who was found to be Addisonian. Despite potentially overlapping neurologic toxicities of the two agents, only two patients (6%) were removed from the study because of progressive peripheral neuropathy. CONCLUSION: Administration of 96-hour paclitaxel infusion and subsequent weekly vinorelbine with G-CSF support is well tolerated. The response rate, TTP, and survival data are encouraging for therapy given to anthracycline pretreated patients with metastatic breast cancer. If these results can be verified in multi-institution trials, this or a similar combination of drugs would merit investigation as first-line therapy in this patient population.
- 1 May 1999
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (5) , 1407
Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy With Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I-II Study of Doxorubicin-Treated Patients
PURPOSE: We investigated 96-hour paclitaxel infusion combined with weekly (days eight and 15) vinorelbine as salvage therapy for metastatic breast cancer in anthracycline-exposed patients. All patients received scheduled support with granulocyte colony-stimulating factor (G-CSF; filgrastim). Tumor response, toxicity, time to progression (TTP), and survival were assessed. PATIENTS AND METHODS: This single-center nonrandomized trial enrolled 32 patients. Anthracycline exposure and subsequent progression were common to all patients. Paclitaxel and vinorelbine were escalated over three dosing levels, stratified by liver function. RESULTS: Seven patients (22%) achieved a complete response and nine patients achieved a partial response for an overall response rate of 50%. The median TTP was 6.1 months, and median survival time was 14.1 months. Dose-limiting toxicity was neutropenia, with dose delay or reduction in seven of 32 patients. Febrile neutropenia requiring hospitalization was uncommon (three of 32 patients; 9%). There were no treatment-related deaths. Grade 3/4 thrombocytopenia occurred in two patients (6%), and 13 patients (41%) required RBC transfusions for anemia. Grade 3 nausea and vomiting was seen in one patient, who was found to be Addisonian. Despite potentially overlapping neurologic toxicities of the two agents, only two patients (6%) were removed from the study because of progressive peripheral neuropathy. CONCLUSION: Administration of 96-hour paclitaxel infusion and subsequent weekly vinorelbine with G-CSF support is well tolerated. The response rate, TTP, and survival data are encouraging for therapy given to anthracycline pretreated patients with metastatic breast cancer. If these results can be verified in multi-institution trials, this or a similar combination of drugs would merit investigation as first-line therapy in this patient population.